AP
REGN icon

Advisor Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Advisor Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$991K Sell
1,677
-77
-4% -$50.1K 0.07% 292
2022
Q1 		$1.23M Buy
1,754
+176
+11% +$111K 0.08% 251
2021
Q4 		$997K Buy
1,578
+26
+2% +$16K 0.06% 304
2021
Q3 		$939K Buy
1,552
+31
+2% +$19.2K 0.06% 291
2021
Q2 		$850K Sell
1,521
-59
-4% -$29.9K 0.06% 332
2021
Q1 		$748K Sell
1,580
-126
-7% -$61.3K 0.05% 362
2020
Q4 		$824K Sell
1,706
-470
-22% -$254K 0.06% 302
2020
Q3 		$1.22M Sell
2,176
-254
-10% -$154K 0.1% 174
2020
Q2 		$1.51M Buy
2,430
+631
+35% +$358K 0.14% 145
2020
Q1 		$878K Buy
1,799
+933
+108% +$385K 0.11% 182
2019
Q4 		$338K Buy
866
+42
+5% +$14.1K 0.03% 455
2019
Q3 		$229K Buy
824
+65
+9% +$19.2K 0.03% 576
2019
Q2 		$238K Sell
759
-430
-36% -$143K 0.03% 548
2019
Q1 		$488K Sell
1,189
-23
-2% -$9.47K 0.06% 306
2018
Q4 		$453K Buy
1,212
+255
+27% +$93.3K 0.07% 291
2018
Q3 		$387K Buy
957
+60
+7% +$22.8K 0.05% 374
2018
Q2 		$309K Buy
897
+28
+3% +$8.76K 0.05% 407
2018
Q1 		$299K Sell
869
-719
-45% -$250K 0.06% 392
2017
Q4 		$590K Buy
1,588
+12
+0.8% +$4.86K 0.11% 226
2017
Q3 		$705K Sell
1,576
-97
-6% -$46.2K 0.14% 162
2017
Q2 		$822K Buy
1,673
+253
+18% +$111K 0.19% 127
2017
Q1 		$550K Sell
1,420
-43
-3% -$15.9K 0.15% 170
2016
Q4 		$537K Buy
1,463
+393
+37% +$149K 0.16% 157
2016
Q3 		$430K Buy
1,070
+209
+24% +$83.8K 0.14% 173
2016
Q2 		$301K Buy
861
+39
+5% +$15K 0.11% 228
2016
Q1 		$296K Sell
822
-38
-4% -$15.7K 0.11% 219
2015
Q4 		$467K Sell
860
-49
-5% -$26.5K 0.16% 154
2015
Q3 		$423K Sell
909
-33
-4% -$17.7K 0.18% 147
2015
Q2 		$433K Buy
942
+134
+17% +$65.4K 0.17% 173
2015
Q1 		$365K Sell
808
-19
-2% -$8.05K 0.16% 184
2014
Q4 		$339K Buy
827
+109
+15% +$42.9K 0.15% 182
2014
Q3 		$259K Buy
+718
New +$241K 0.15% 175

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Advisor Partners's REGN Position: Q2 2022 in Review

Advisor Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 4.4% in Q2 2022, selling an estimated $50.1K and leaving 1,677 shares worth $991K. The position accounts for 0.07% of the portfolio, ranked #292.

Advisor Partners first reported a position in REGN in Q3 2014 and has held it in 32 quarters since. The position peaked at $1.51M in Q2 2020. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Advisor Partners held 1,677 shares of Regeneron Pharmaceuticals worth $991K as of Q2 2022.
  • Advisor Partners sold 77 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $50.1K.
  • Regeneron Pharmaceuticals made up 0.07% of Advisor Partners's portfolio in Q2 2022, its #292 holding.
  • Advisor Partners first reported a position in Regeneron Pharmaceuticals in Q3 2014 and has held it in 32 quarters since.
  • Advisor Partners's Regeneron Pharmaceuticals position peaked at $1.51M in Q2 2020.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.